Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIVA-2: givastomig plus nivolumab and chemotherapy versus nivolumab plus chemotherapy in first-line CLDN18.2-positive and PD-L1-positive advanced gastric/GEJ/esophageal adenocarcinoma
CTR20260642Phase 2Active
- Sponsor
- I-Mab
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of givastomig, nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by I-Mab. Started May 2026; status: active.
02
Drugs
givastomignivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20260642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260642.